BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

About BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals logoBioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:BCRX
  • CUSIP: 09058V10
  • Web:
  • Market Cap: $408.57 million
  • Outstanding Shares: 80,428,000
Average Prices:
  • 50 Day Moving Avg: $5.25
  • 200 Day Moving Avg: $5.62
  • 52 Week Range: $3.75 - $9.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.51
  • P/E Growth: -0.34
Sales & Book Value:
  • Annual Revenue: $29.28 million
  • Price / Sales: 13.95
  • Book Value: $0.30 per share
  • Price / Book: 16.93
  • EBITDA: ($42,940,000.00)
  • Net Margins: -544.89%
  • Return on Equity: -216.37%
  • Return on Assets: -55.74%
  • Debt-to-Equity Ratio: 0.94%
  • Current Ratio: 1.57%
  • Quick Ratio: 1.54%
  • Average Volume: 1.55 million shs.
  • Beta: 3.37
  • Short Ratio: 17.05

Frequently Asked Questions for BioCryst Pharmaceuticals (NASDAQ:BCRX)

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) posted its quarterly earnings data on Monday, August, 7th. The company reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.02. The company earned $3.10 million during the quarter, compared to analyst estimates of $5.79 million. BioCryst Pharmaceuticals had a negative net margin of 544.89% and a negative return on equity of 216.37%. The business's revenue for the quarter was down 35.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.22) earnings per share. View BioCryst Pharmaceuticals' Earnings History.

When will BioCryst Pharmaceuticals make its next earnings announcement?

BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for BioCryst Pharmaceuticals.

Where is BioCryst Pharmaceuticals' stock going? Where will BioCryst Pharmaceuticals' stock price be in 2017?

10 analysts have issued 1-year target prices for BioCryst Pharmaceuticals' shares. Their forecasts range from $6.00 to $15.00. On average, they anticipate BioCryst Pharmaceuticals' stock price to reach $9.25 in the next year. View Analyst Ratings for BioCryst Pharmaceuticals.

What are analysts saying about BioCryst Pharmaceuticals stock?

Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (8/10/2017)
  • 2. Needham & Company LLC analysts commented, "Shire (SHPG) reported positive results from the ph 3 HELP trial evaluating lanadelumab (fka SHP643) as a prophylactic HAE treatment. Lanadelumab, an antibody that binds and inhibits plasma kallikrein, is formulated for subcutaneous administration and has a long half-life (~14 days) that enables once- or twice-monthly dosing. The HELP trial met all of its endpoints; monthly attack rate reduction vs. placebo for all dosing regimens ranged from 73% – 87% (p<0.001). A BLA filing for lanadelumab is expected in late-2017/early-2018. BCRX's BCX7353, a daily orally-administered HAE prophylactic candidate, is currently under evaluation in the ph 2 APeX-1 trial. Positive interim results reported in late-Feb showed that BCX7353 led to a ~52% HAE attack rate reduction (p=0.035, ITT), with results showing a dichotomy of efficacy between peripheral attacks (~88% reduction) and abdominal attacks (~24% reduction). Additional APeX-1 cohorts evaluating lower-doses of BCX7353 are expected to report in 2Q17. These data should provide clarity on the efficacy/tolerability profile of BCX7353 and help shed some light on its potential role in HAE prophylaxis."" (5/19/2017)

Are investors shorting BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals saw a decrease in short interest in the month of September. As of September 29th, there was short interest totalling 10,746,206 shares, a decrease of 25.1% from the September 15th total of 14,348,677 shares. Based on an average trading volume of 2,214,130 shares, the days-to-cover ratio is currently 4.9 days. Approximately 11.1% of the company's stock are short sold.

Who are some of BioCryst Pharmaceuticals' key competitors?

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the folowing people:

  • Robert A. Ingram, Chairman of the Board
  • Jon P. Stonehouse, President, Chief Executive Officer, Director
  • Thomas R. Staab II, Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer
  • Yarlagadda S. Babu Ph.D., Senior Vice President - Drug Discovery
  • Lynne M Powell, Senior Vice President, Chief Commercial Officer
  • William P. Sheridan, Senior Vice President, Chief Medical Officer
  • Alane P. Barnes, Vice President, General Counsel, and Corporate Secretary
  • Fred E. Cohen Ph.D. M.D., Director
  • Sanj K. Patel, Director
  • George B. Abercrombie, Independent Director

How do I buy BioCryst Pharmaceuticals stock?

Shares of BioCryst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioCryst Pharmaceuticals' stock price today?

One share of BioCryst Pharmaceuticals stock can currently be purchased for approximately $5.08.

MarketBeat Community Rating for BioCryst Pharmaceuticals (NASDAQ BCRX)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  216 (Vote Underperform)
Total Votes:  466
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $9.25 (82.09% upside)
Consensus Price Target History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Price Target History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Analysts' Ratings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform -> Sector Perform$6.00LowView Rating Details
9/6/2017HC WainwrightReiterated RatingBuy$10.00HighView Rating Details
9/6/2017J P Morgan Chase & CoBoost Price TargetOverweight -> Neutral$4.93 -> $9.00HighView Rating Details
9/6/2017Jefferies Group LLCUpgradeHold -> Buy$5.00 -> $7.00HighView Rating Details
9/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$13.00 -> $15.00HighView Rating Details
8/8/2017Noble FinancialReiterated RatingBuyLowView Rating Details
5/19/2017Needham & Company LLCReiterated RatingHoldMediumView Rating Details
2/16/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$11.00N/AView Rating Details
1/23/2017FBR & CoReiterated RatingOutperformN/AView Rating Details
12/16/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$10.00N/AView Rating Details
2/9/2016Rodman & RenshawLower Price TargetBuy$24.00 -> $10.00N/AView Rating Details
11/11/2015Bank of America CorporationDowngradeNeutral -> Underperform$12.00 -> $10.00N/AView Rating Details
11/10/2015Oppenheimer Holdings, Inc.Reiterated RatingMarket PerformN/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Earnings by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Earnings History by Quarter for BioCryst Pharmaceuticals (NASDAQ BCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.18)N/AView Earnings Details
8/7/2017Q2 2017($0.19)($0.21)$5.79 million$3.10 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.20)($0.19)$6.13 million$9.40 millionViewListenView Earnings Details
2/27/2017Q416($0.23)($0.06)$4.13 million$9.00 millionViewListenView Earnings Details
11/7/2016Q316($0.24)($0.16)$5.94 million$7.80 millionViewListenView Earnings Details
8/4/2016Q216($0.26)($0.22)$3.92 million$4.80 millionViewN/AView Earnings Details
5/5/2016Q116($0.23)($0.31)$5.42 million$4.82 millionViewN/AView Earnings Details
2/23/2016Q415($0.26)($0.25)$6.34 million$4.60 millionViewListenView Earnings Details
11/5/2015Q315($0.20)($0.20)$6.77 million$11.00 millionViewListenView Earnings Details
8/7/2015Q215($0.22)$0.06$7.10 million$25.80 millionViewListenView Earnings Details
5/8/2015Q115($0.24)($0.21)$4.30 million$6.80 millionViewListenView Earnings Details
2/18/2015Q414($0.20)($0.16)$3.64 million$5.40 millionViewListenView Earnings Details
11/6/2014Q314($0.20)($0.12)$2.11 million$3.20 millionViewListenView Earnings Details
8/5/2014Q214($0.19)($0.23)$2.32 million$1.50 millionViewN/AView Earnings Details
5/8/2014Q114($0.16)($0.17)$3.34 million$3.50 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.09)$8.81 million$10.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.14)($0.14)$2.01 million$2.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.14)($0.23)$2.01 million$0.82 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.15)($0.09)$1.31 million$3.60 millionViewN/AView Earnings Details
2/19/2013Q4 2012($0.16)($0.22)$4.02 million$4.10 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.19)$4.63 million$5.80 millionViewN/AView Earnings Details
8/2/2012($0.26)($0.25)ViewN/AView Earnings Details
5/7/2012($0.26)($0.13)ViewN/AView Earnings Details
2/16/2012($0.33)($0.29)ViewN/AView Earnings Details
11/2/2011($0.30)($0.32)ViewN/AView Earnings Details
8/4/2011($0.26)($0.36)ViewN/AView Earnings Details
5/4/2011($0.20)($0.29)ViewN/AView Earnings Details
2/10/2011($0.21)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)
2017 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.14)($0.14)($0.14)
Q2 20171($0.17)($0.17)($0.17)
Q3 20171($0.13)($0.13)($0.13)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)


Dividend History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 70.21%
Insider Trades by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Insider Trades by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/18/2017Fred E CohenDirectorSell54,250$5.42$294,035.00View SEC Filing  
3/20/2017Thomas R Staab IICFOSell3,250$9.20$29,900.00View SEC Filing  
3/10/2017Thomas R Staab IIInsiderSell3,250$9.06$29,445.00View SEC Filing  
3/8/2017Thomas R Staab IIInsiderSell6,500$8.43$54,795.00View SEC Filing  
3/6/2017Thomas R Staab IIInsiderSell3,250$7.90$25,675.00View SEC Filing  
12/19/2016Thomas R Staab IIInsiderSell3,250$7.45$24,212.50View SEC Filing  
9/14/2016Alane P BarnesVPSell8,357$4.27$35,684.39View SEC Filing  
8/25/2016Yarlagadda S BabuVPSell30,000$4.06$121,800.00View SEC Filing  
8/16/2016Bros. Advisors Lp BakerMajor ShareholderSell4,046,590$5.00$20,232,950.00View SEC Filing  
8/12/2016Thomas R Staab IIInsiderSell5,864$5.18$30,375.52View SEC Filing  
8/9/2016Thomas R Staab IIInsiderSell14,577$4.43$64,576.11View SEC Filing  
1/28/2016Bros. Advisors Lp Bakermajor shareholderBuy88,345$6.95$613,997.75View SEC Filing  
1/22/2016Bros. Advisors Lp Bakermajor shareholderBuy106,800$7.28$777,504.00View SEC Filing  
1/20/2016Bros. Advisors Lp Bakermajor shareholderBuy52,695$6.87$362,014.65View SEC Filing  
1/19/2016Bros. Advisors Lp Bakermajor shareholderBuy92,200$7.12$656,464.00View SEC Filing  
1/15/2016Bros. Advisors Lp Bakermajor shareholderBuy200,000$7.46$1,492,000.00View SEC Filing  
12/21/2015Thomas R Staab IICFOSell3,052$10.86$33,144.72View SEC Filing  
12/17/2015Thomas R Staab IICFOSell3,000$10.49$31,470.00View SEC Filing  
7/20/2015Thomas R Staab IICFOSell3,500$16.50$57,750.00View SEC Filing  
6/22/2015Thomas R Staab IICFOSell3,750$16.00$60,000.00View SEC Filing  
6/19/2015Alane P BarnesVPSell3,000$15.00$45,000.00View SEC Filing  
6/19/2015Jon P StonehouseCEOSell20,000$15.02$300,400.00View SEC Filing  
6/19/2015Thomas R Staab IICFOSell16,375$14.36$235,145.00View SEC Filing  
6/19/2015William P SheridanCMOSell70,389$15.05$1,059,354.45View SEC Filing  
6/5/2015Thomas R Staab IICFOSell6,000$12.75$76,500.00View SEC Filing  
5/18/2015Thomas R Staab IICFOSell3,000$11.00$33,000.00View SEC Filing  
3/19/2015Yarlagadda S BabuVPSell12,105$10.16$122,986.80View SEC Filing  
3/5/2015Yarlagadda S BabuVPSell37,400$10.59$396,066.00View SEC Filing  
3/4/2015Yarlagadda S BabuVPSell10,495$10.50$110,197.50View SEC Filing  
2/20/2015Nancy J HutsonDirectorBuy10,000$10.27$102,700.00View SEC Filing  
12/30/2014William P SheridanCMOSell128,399$12.36$1,587,011.64View SEC Filing  
12/29/2014Thomas R Staab IICFOSell9,500$12.56$119,320.00View SEC Filing  
12/29/2014William P SheridanCMOSell105,295$12.43$1,308,816.85View SEC Filing  
8/27/2014Thomas R Staab IICFOSell10,000$13.58$135,800.00View SEC Filing  
7/1/2014Thomas R Staab IICFOSell3,125$13.00$40,625.00View SEC Filing  
6/23/2014Thomas R Staab IICFOSell3,125$12.49$39,031.25View SEC Filing  
6/17/2014Thomas R Staab IICFOSell3,125$12.00$37,500.00View SEC Filing  
3/14/2014Thomas Staab IICFOSell3,125$11.24$35,125.00View SEC Filing  
3/6/2014Kenneth Lee, Jr.DirectorSell12,665$12.69$160,718.85View SEC Filing  
11/12/2013George AbercrombieDirectorBuy3,000$6.19$18,570.00View SEC Filing  
8/1/2013Felix BakerMajor ShareholderBuy1,136,364$4.40$5,000,001.60View SEC Filing  
3/5/2013George B AbercrombieDirectorBuy3,000$1.23$3,690.00View SEC Filing  
12/14/2012Peder JensenDirectorBuy20,000$1.51$30,200.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Latest Headlines for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateHeadline logoETFs with exposure to BioCryst Pharmaceuticals, Inc. : October 17, 2017 - October 17 at 5:16 PM logoShort Interest in BioCryst Pharmaceuticals, Inc. (BCRX) Drops By 25.1% - October 13 at 1:32 AM logoBioCryst Pharmaceuticals, Inc. (BCRX) Expected to Post Quarterly Sales of $5.16 Million - October 9 at 5:24 AM logoZacks: Analysts Expect BioCryst Pharmaceuticals, Inc. (BCRX) to Announce -$0.17 EPS - October 7 at 4:08 PM logoETFs with exposure to BioCryst Pharmaceuticals, Inc. : October 3, 2017 - October 3 at 4:13 PM logoBioCryst Pharmaceuticals (BCRX) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow - September 28 at 4:47 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) Short Interest Up 14.2% in September - September 28 at 3:18 AM logoFew Biotech Stocks Keep Momentum Going With Key Developments and FDA Approvals - September 27 at 7:40 PM logoBioCryst Pharmaceuticals (BCRX) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow - September 27 at 7:40 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) Receives Consensus Rating of "Hold" from Analysts - September 27 at 2:32 PM logoCan BioCryst Turn Itself Around With This FDA Approval? - 24/7 Wall St. - September 23 at 1:27 AM logoBioCryst’s RAPIVAB® (peramivir injection) Receives FDA Approval for a Pediatric Indication - September 22 at 12:48 PM logoHave Investors Already Priced In BioCryst Pharmaceuticals Inc’s (BCRX) Growth? - September 22 at 12:48 PM logoCan BioCryst Turn Itself Around With This FDA Approval? - September 22 at 12:48 PM logoBioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017 - September 22 at 12:48 PM logoBioCryst scores FDA approval on flu treatment for children - September 22 at 12:48 PM logoETFs with exposure to BioCryst Pharmaceuticals, Inc. : September 22, 2017 - September 22 at 12:48 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) Director Fred E. Cohen Sells 54,250 Shares - September 20 at 1:16 PM logo$5.16 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter - September 20 at 3:56 AM logo Brokerages Expect BioCryst Pharmaceuticals, Inc. (BCRX) to Post -$0.17 Earnings Per Share - September 18 at 10:28 PM logoBioCryst Meeting with FDA to Design Phase III Trial for BCX7353 and PDUFA Review for RAPIVAB - September 15 at 4:52 PM logoBioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock - September 15 at 4:52 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) Receives New Coverage from Analysts at Royal Bank Of Canada - September 14 at 11:06 PM logo​How BioCryst aims to use its $80M public offering - September 14 at 5:07 PM logoBioCryst Pharma (BCRX) Prices 15.53M Share Common Offering at ... - - September 13 at 10:40 PM logoBioCryst Prices Offering At $5.15/Share - September 13 at 5:36 PM logoBioCryst Pharma (BCRX) Prices 15.53M Share Common Offering at $5.15/Sh - September 13 at 5:36 PM logo5 Stocks To Watch For September 12, 2017 | Benzinga - Benzinga - September 12 at 8:22 PM logoBioCryst Pharmaceuticals Commences Public Offering of Common Stock - GlobeNewswire (press release) - September 12 at 3:22 PM logoBioCryst Pharmaceuticals Announces Secondary Offering - 24/7 Wall St. - September 12 at 3:21 PM logoAfter-Hours Stock Movers 09/11: (WDC) (LAYN) Higher; (BCRX) (PTLA) (FDC) Lower (more...) - September 11 at 10:07 PM logoJefferies Group Analysts Lower Earnings Estimates for BioCryst Pharmaceuticals, Inc. (BCRX) - September 8 at 11:38 AM logoBioCryst Pharmaceuticals (BCRX) Presents At Baird's 2017 Global Healthcare Conference - Slideshow - September 7 at 4:32 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) Receives Buy Rating from HC Wainwright - September 6 at 9:02 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) Price Target Raised to $9.00 - September 6 at 9:33 AM logoBioCryst Pharmaceuticals, Inc. (BCRX) Raised to Buy at Jefferies Group LLC - September 6 at 8:38 AM logoBioCryst Pharma (BCRX) Phase 2 Trial of APeX-1 Shows Positive Efficacy and Tolerability - - September 5 at 11:12 PM logoBioCryst Flat Despite Positive Treatment Results - September 5 at 6:05 PM logoBioCryst Pharma (BCRX) Phase 2 Trial of APeX-1 Shows Positive Efficacy and Tolerability - September 5 at 6:05 PM logoBioCryst Pharmaceuticals (BCRX) Updates On Final Analysis Results (BCX7353 -APeX-1) - Slideshow - September 5 at 6:05 PM logoBioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE - September 5 at 6:05 PM logoBioCryst Pharma Sees Brief Surge on Mid-Stage Trial Win - September 5 at 6:05 PM logoJPMorgan Chase & Co. Upgrades BioCryst Pharmaceuticals, Inc. (BCRX) to Overweight - September 5 at 5:16 PM logoPiper Jaffray Companies Reiterates "Overweight" Rating for BioCryst Pharmaceuticals, Inc. (BCRX) - September 5 at 11:10 AM logoBioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Rating of "Buy" from Brokerages - September 2 at 2:38 PM logo Brokerages Anticipate BioCryst Pharmaceuticals, Inc. (BCRX) Will Announce Quarterly Sales of $5.16 Million - September 2 at 9:52 AM logoIs the Options Market Predicting a Spike in BioCryst (BCRX) Stock? - Nasdaq - September 1 at 3:35 PM logoIs the Options Market Predicting a Spike in BioCryst (BCRX) Stock? - September 1 at 3:35 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) Expected to Announce Earnings of -$0.17 Per Share - August 31 at 10:38 AM logoBioCryst to Present at Three Upcoming Investor Conferences - August 23 at 6:10 AM



BioCryst Pharmaceuticals (BCRX) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.